BNP Paribas Financial Markets Sells 59,118 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Posted by George Bondi on Jun 7th, 2026

BNP Paribas Financial Markets lessened its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 26.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 164,563 shares of the company’s stock after selling 59,118 shares during the period. BNP Paribas Financial Markets’ holdings in Rhythm Pharmaceuticals were worth $17,615,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of RYTM. Vanguard Group Inc. raised its stake in Rhythm Pharmaceuticals by 39.2% during the third quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock worth $504,589,000 after buying an additional 1,407,313 shares during the last quarter. Alliancebernstein L.P. increased its stake in Rhythm Pharmaceuticals by 1,493.8% in the third quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock valued at $98,938,000 after purchasing an additional 918,212 shares in the last quarter. Capital Research Global Investors bought a new stake in Rhythm Pharmaceuticals in the third quarter valued at $60,417,000. Jennison Associates LLC increased its stake in Rhythm Pharmaceuticals by 123.2% in the fourth quarter. Jennison Associates LLC now owns 918,567 shares of the company’s stock valued at $98,323,000 after purchasing an additional 507,017 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Rhythm Pharmaceuticals by 51.6% in the third quarter. JPMorgan Chase & Co. now owns 1,188,069 shares of the company’s stock valued at $119,983,000 after purchasing an additional 404,510 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on RYTM shares. Wells Fargo & Company lifted their price target on shares of Rhythm Pharmaceuticals from $143.00 to $144.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. HC Wainwright decreased their price target on shares of Rhythm Pharmaceuticals from $110.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. Bank of America decreased their price target on shares of Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. Citigroup reiterated a “market outperform” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday. Finally, Jefferies Financial Group restated a “buy” rating and issued a $125.00 target price on shares of Rhythm Pharmaceuticals in a report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $131.81.

Check Out Our Latest Analysis on Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ RYTM opened at $86.40 on Friday. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $60.70 and a fifty-two week high of $122.20. The stock has a market cap of $5.92 billion, a price-to-earnings ratio of -27.60 and a beta of 1.91. The firm’s 50-day simple moving average is $87.45 and its 200 day simple moving average is $96.82.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.03. Rhythm Pharmaceuticals had a negative net margin of 93.33% and a negative return on equity of 203.25%. The business had revenue of $60.11 million for the quarter, compared to analysts’ expectations of $55.78 million. During the same period in the previous year, the company earned ($0.81) earnings per share. The firm’s revenue for the quarter was up 83.8% compared to the same quarter last year. On average, sell-side analysts predict that Rhythm Pharmaceuticals, Inc. will post -3.07 EPS for the current year.

About Rhythm Pharmaceuticals

(Free Report)

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.